REDWOOD CITY, Calif. & BOSTON, November 01, 2024--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that company management will participate in three upcoming investor conferences in November.

Details of the events are as follows:

Truist Securities BioPharma Symposium, November 7, 2024, New York, NY

• Members of management will be available for 1x1 meetings on November 7, 2024

Guggenheim Securities Healthcare Innovation Conference, November 11-13, 2024, Boston, MA

• Chen Schor, President and Chief Executive Officer, will participate in a fireside chat on November 12, 2024 at 3:00 p.m. ET

Jefferies London Healthcare Conference, November 19-21, 2024, London

• Chen Schor, President and Chief Executive Officer, will participate in a fireside chat on November 19, 2024 at 12:30 p.m. BST

The live audio webcasts of the fireside chats can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241101153157/en/

Contacts

Adicet Bio, Inc.
Investor and Media Contacts

Investors:
Anne Bowdidge
abowdidge@adicetbio.com

Janhavi Mohite
Precision AQ
212-362-1200
janhavi.mohite@precisionaq.com

Media:
Kerry Beth Daly
kbdaly@adicetbio.com